Lu Fenghe

Aihara Makoto, Lu Fenghe, Ikeda Toshihiro, Odani-Kawabata Noriko

This study found preservative-free and preserved omidenepag isopropyl drops are equally effective at lowering eye pressure. This offers a valuable preservative-free option for glaucoma/ocular hypertension patients, potentially reducing ocular surface irritation.

Bacharach Jason, Brubaker Jacob W, Evans David G, Lu Fenghe, Odani-Kawabata Noriko, Yamabe Takaharu et al.

Two studies found omidenepag isopropyl effectively lowers IOP in glaucoma/OHT, non-inferior to timolol over 3 months, with sustained 12-month efficacy, offering a new treatment option.

Olander Kenneth W, Sato Michelle A, Abrams Marc A, Jerkins Gary W, Lu Fenghe, Dinh Phillip et al.

Omidenepag isopropyl for glaucoma showed similar IOP reduction with once-daily (QD) versus twice-daily (BID) dosing. However, BID dosing had significantly more adverse events, making QD the preferred regimen for future study.

Aihara Makoto, Lu Fenghe, Kawata Hisashi, Iwata Akihiro, Odani-Kawabata Noriko, Shams Naveed K

OMDI, a new glaucoma drug, was non-inferior to latanoprost in lowering IOP in glaucoma/OHT patients. This provides an alternative treatment option.

Aihara Makoto, Lu Fenghe, Kawata Hisashi, Iwata Akihiro, Liu Kathy, Odani-Kawabata Noriko et al.

Omidenepag isopropyl effectively lowered IOP in glaucoma/ocular hypertension patients, with 0.002% identified as the optimal, well-tolerated dose for further study, offering a new potential treatment option.